Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- Today, on the final day of the annual meeting of the American Society of Hematology (ASH), Richard Furman presented exciting results from a planned interim analysis of a Phase III, randomized double-blind, placebo-controlled study evaluating efficacy and safety of idelalisib (GS-1101, Gilead Sciences) and Rituxan® (rituximab, Genentech/Roche) for previously-treated patients with chronic lymphocytic leukemia (CLL).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- The ASH 2013 meeting is ripe with new data in the treatment of chronic lymphocytic leukemia (CLL), with particular focus on high unmet need populations, such as relapsed/refractory disease and patients “unfit” for intensive chemoimmunotherapy. Impressive results from the Phase III CLL11 trial of Gazyva (obinutuzumab, Genentech/Roche) were presented in during the plenary session on December 8. On December 9, two back-to-back oral sessions highlighted several other advances in the treatment of CLL, including results from the Phase III COMPLEMENT-1 trial of Arzerra.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- Multiple Myeloma has had significant new advances in the past year, with the U.S. Food and Drug Administration (FDA) approval of Kyprolis® (carfilzomib, Onyx/Amgen) and the U.S. and European approvals of Pomalyst® (Imnovid® in Europe, pomalidomide, Celgene), both in the relapsed/refractory setting. The relapsed/refractory setting is poised for further evolution with the recently announced success of the PANORAMA-2 Phase III trial of panobinostat (LBH589, Novartis) and ongoing Phase III trials with numerous other promising agents.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- CLL is a disease of the elderly, with a median age of diagnosis at 71 in the U.S. and nearly 40% of patients older than 75 at the time of diagnosis. Standard treatment for “fit” patients is aggressive chemotherapy, but existing comorbidities in elderly patients frequently preclude use of these highly toxic regimens. Phase III trials are ongoing or recently completed for Arzerra, ibrutinib , and Gazyva.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- In recent years, angiogenesis inhibition, and VEGFR inhibition in particular, has been the most promising therapeutic target in advanced ovarian cancer, and the VEGF-targeted monoclonal antibody Avastin® (bevacizumab, Roche/Genentech) has been the major player in drug development for this tumor type. With Phase III trials conducted in multiple settings in ovarian cancer, Avastin has demonstrated a progression-free survival (PFS) benefit in first-line, recurrent platinum-sensitive, and recurrent platinum-resistant patients, and in the past two years, it has received regulatory approval in the European Union for use in the first-line/maintenance and recurrent platinum-sensitive settings.
    Continue Reading > | Go comment! | Share